What is the specific mechanism of action of fotantinib/fotantinib?

Fostamatinib is an oral small molecule tyrosine kinase inhibitor that is an immunomodulatory drug. It was first developed by Rigel Pharmaceuticals and has been approved for marketing in some countries under the trade name Tavalisse. Its core mechanism of action is to regulate abnormal activity of the immune system by inhibiting Spleen Tyrosine Kinase (SYK). SYK is an intracellular signal transduction protein that is widely involved in the activation process of a variety of immune cells, especially playing a key role in the signaling of B cell receptors, Fc receptors, T cells and inflammatory factors.

Fotantinib is a prodrug that is quickly converted into its active form after oral administration into the bodyR406, and inhibits SYK activity in the body. By inhibiting the function of this enzyme, fotantinib can interfere with immune cell activation, antibody-dependent cellular phagocytosis (ADCP), and the release of various inflammatory mediators, thereby reducing inflammation and tissue damage in autoimmune-related lesions.

Fotantinib is currently mainly used to treat chronic immune thrombocytopenia (ITP), especially for patients who have failed to respond to or relapsed after first-line treatment. In ITP, the patient's immune system mistakenly regards platelets as "invaders" and prompts macrophages to engulf platelets through an Fcγ receptor-mediated mechanism, resulting in an abnormal decrease in platelet levels. SYK plays a central role in this process, so fotantinib helps inhibit platelet clearance by macrophages by blocking this pathway.

In addition, the potential application of fotantinib in diseases such as rheumatoid arthritis, systemic lupus erythematosus, and IgA nephropathy is also being studied, especially in cases where traditional immunosuppressants are ineffective or have severe side effects.

Reference materials:https://go.drugbank.com/drugs/DB12010